Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic accuracy study of the multiplex Truenat MTB Ultima/COVID-19 assay for simultaneous detection of Tuberculosis and SARS-CoV2 (COVID-19).

PLOS global public health·2026
Same author

Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development.

The Lancet. Infectious diseases·2026
Same author

Multicountry assessment of tongue swabs for tuberculosis using a common protocol for Xpert MTB/RIF Ultra testing: a prospective diagnostic accuracy study.

The Lancet. Microbe·2026
Same author

User perspectives on the Molbio Truenat platform and tuberculosis assays for decentralised testing in Mozambique and Tanzania.

BMJ global health·2026
Same author

Expanding Xpert MTB/RIF Ultra and lateral flow urine lipoarabinomannan testing for diagnosis of tuberculosis among adults living with HIV admitted to hospitals in Tanzania and Mozambique (EXULTANT): a randomised controlled trial.

The Lancet. Infectious diseases·2026
Same author

Accuracy and clinical utility of near-point-of-care blood tests for predicting incident tuberculosis in exposed contacts in high burden settings: a multi-country observational cohort study.

Research square·2026

Related Experiment Video

Updated: Apr 26, 2026

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

13.8K

Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.

Yali Qin1, Marisa Banasik1, SoonJeung Kim2

  • 1Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, United States; Center for Advanced Host Defenses, Immunobiotics and Translational Comparative Medicine, Iowa State University, Ames, IA 50011, United States.

Virology
|July 22, 2014
PubMed
Summary

Developing novel HIV-1 vaccines, researchers created gp120 outer domain (OD) immunogens. The trimeric gp120-OD×3 construct effectively induced potent, cross-reactive neutralizing antibodies (nAbs) in rabbits, showing promise for future vaccine development.

Keywords:
HIV-1Neutralizing antibodyOuter domainV3Vaccinegp120

More Related Videos

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.4K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

9.6K

Related Experiment Videos

Last Updated: Apr 26, 2026

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

13.8K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.4K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

9.6K

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • HIV-1 vaccine development aims to elicit neutralizing antibodies (nAbs).
  • Focusing immune responses on the gp120 outer domain (OD) involves removing the inner domain.
  • Previous OD constructs failed to induce strong nAbs.

Purpose of the Study:

  • To develop and evaluate novel gp120 outer domain (OD) immunogens for HIV-1 vaccine development.
  • To compare the biochemical and immunological properties of monomeric and trimeric gp120-OD constructs.
  • To assess the immunogenicity and antibody responses elicited by these novel immunogens.

Main Methods:

  • Construction of monomeric gp120-OD and trimeric gp120-OD×3 immunogens based on an M group consensus sequence (MCON6).
  • Biochemical and immunological characterization of the immunogens compared to intact gp120.
  • Immunization of rabbits and analysis of induced neutralizing antibody (nAb) responses, including potency, breadth, and epitope mapping.

Main Results:

  • The trimeric gp120-OD×3 construct demonstrated better preservation of critical neutralizing epitopes.
  • Both gp120-OD and gp120-OD×3 immunogens induced potent, cross-reactive nAbs in rabbits, targeting Tier 1 viruses with significant breadth.
  • nAb induction kinetics revealed the superiority of gp120-OD×3 over gp120-OD.

Conclusions:

  • The trimeric gp120-OD×3 immunogen is a promising prototype for HIV-1 vaccine development.
  • Targeting conserved V3 loop elements via OD constructs can elicit broadly neutralizing antibodies.
  • Further development of gp120 OD-based immunogens holds potential for effective HIV-1 vaccines.